Introduction
Although loop diuretics are more effective than thiazide diuretics in the treatment of acute oedema, both types of diuretic appear to be equally effective when used in small maintenance doses (Playfair, 1975) . Consequently, for maintenance treatment of heart failure, the choice of diuretic may be left to the patient, some preferring the short, predictable effect of the loop diuretics, others preferring the milder, more sustained effect of the thiazides (Watt, 1978) . The 2 groups of diuretic may differ in their effects on plasma biochemical variables. In comparison with thiazide diuretics, loop diuretics are said to be less likely to produce hypokalaemia (Morgan and Davidson, 1980; Duchin and Hutcheon, 1976) , hyperuricaemia (Wyngaarden and Kelly, 1978) , and, possibly, disturbances in carbohydrate metabolism (Dollery, 1973) . Thiazide diuretics reduce the urinary excretion of calcium, while loop diuretics, at least in the short-term, increase it (Eknoyan, Suki and Martinez-Maldonado, 1970; Pak, 1973) . Differences may also occur among individual loop diuretics. Several studies have suggested that potassium excretion following bumetanide is less marked than following frusemide (Dunn et al., 1975; Ramsay et al., 1978) . Differences in urate and magnesium metabolism have also been described (Davies et al., 1974; Editorial, 1975) .
To investigate these reported differences, a fully balanced, cross-over study was Patients were investigated one week before entering the trial, at the time of entry (time 0) and at monthly intervals for 9 months. On each visit to the out-patient clinic, patients were weighed under standard conditions. Non-fasting blood was taken for measurement of sodium, potassium, bicarbonate, magnesium, calcium, glucose, creatinine, urea, urate, cholesterol and triglycerides. Samples were taken between 9 a.m. and 11 a.m. on Monday mornings. In order to increase the precision of the measurements at 0, 3, 6 and 9 months, 2 separate samples of blood were taken from each patient. The mean of duplicates was used in subsequent calculations, with the exception that for the baselines, the concentration reported at time -1 week was combined with the time 0 duplicate measurement.
Statistical analysis was performed on each of the 11 variables by subtracting the combined baseline mean from the mean at 3, 6, and 9 months. These changes were then further studied by the analysis of variance in order to test the significance between the effects of treatments, the 3-monthly periods of treatment, the 6 different orders in which the treatments were given, and any possible interaction. The error variance derived from the analysis of variance was used to calculate linear comparisons between the mean changes brought about by the 3 diuretics, and to set confidence limits (Snedecor and Cochran, 1967) .
Each patient was asked to state a preference for a particular diuretic after 6 and 9 months. The details of the analysis of variance with respect to the potassium data are shown in Table 2 . Since a significant difference was observed between treatments, it was appropriate to compare the changes in plasma potassium concentration brought about between pairs of diuretics and to set confidence limits (Table 3 ). Thus the difference between the changes in plasma potassium produced by bumetanide and bendrofluazide was 0-49 mmol/l, with a lower and upper confidence limit (95%) of +0-12 and +0-87 mmol/l respectively. This difference was statistically significant.
In terms of the absolute changes in plasma potassium shown in Table 1 , as distinct from the mean differences between diuretics, bumetanide produced the smallest change (+0-11 mmol/l with 95% confidence limits of -016 to +0-39) and bendrofluazide the greatest change (-0-38 mmol/l with 95% confidence limits of -0-66 to -0-10). Frusemide pro- (Ramsay et al., 1978) . Such inhibition is greater for thiazides than for frusemide, and is marginally greater for frusemide than for bumetanide (Puschett and Rastegar, 1974; Lant, 1975) . The propensity of a diuretic to produce hypokalaemia may be related also to its duration of action, the longer acting ones allowing proportionately less time for compensatory renal potassium retention. This hypothesis may explain apparent, although statistically non-significant differences between the action of the 2 loop diuretics on plasma potassium concentrations. The duration of action of bumetanide is marginally shorter than that of frusemide (Bennion-Pedley et al., 1975) , so that disturbances in potassium homoeostasis should be less likely to occur.
This study can be criticized on the grounds that plasma potassium and not total body potassium was measured, and that plasma potassium is not necessarily related directly to total body potassium (Edmonds and Jasani, 1972) . In clinical practice, nevertheless, plasma potassium, not total body potassium, is routinely used as the guide to the need for potassium supplements or a potassium-sparing drug.
The study provides no support for other differences that have been attributed to loop and thiazide diuretics. There was no apparent effect on calcium, lipid, urate or glucose metabolism. This may be related to the short duration of the study, and to the fact that non-fasting blood samples were taken.
These findings raise the question whether potassium supplements are required during long-term use of diuretics. The need for potassium supplements or potassium-sparing drugs appears to be less when using loop diuretics than when using thiazides. However, this is a small study and the risk of hypokalaemia cannot be excluded during treatment with loop diuretics when a much larger population is considered. Even with bumetanide, which appears to be the least likely to produce hypokalaemia, potassium supplements may be required during long-term treatment. 
